

Gene therapy



SPK-8016 Phase 1/2 preliminary data showed a 98% reduction in Annualized Infusion Rate (AIR) and 85% reduction in Annualized Bleeding Rate (ABR) after a follow up of 15-18 months in four patients.

To put the data in perspective to the other two gene therapies in development for Hemophilia A:

- In January 2021, valoctocogene roxaparvovec showed a 99% reduction in AIR and 84% reduction in ABR in a Phase 3 data update with 134 patients.
- In December 2020, giroctocogene fitelparvovec showed a 100% reduction in AIR and 100% reduction in ABR in a Phase 1/2 data update with five patients.

More info at https://sparktx.com/press_releases/eahad_2021/